Infinitus co-organizes “Traditional Chinese Medicine Cultural Communication ▪ We are in Action” event
CAE academician Yu Mengsun and Master of traditional Chinese medicine Zhou Daihan visit Infinitus GUANGZHOU, China, Aug. 27, 2022 /PRNewswire/ -- On August 21, 2022, the Guangdong leg of the "Traditional Chinese Medicine Cultural Communication · We are in Action" event, jointly organized by the China Traditional Chinese Medicine Newspaper Agency, Xinhua News Agency's Economic Information Daily, China...
ProSomnus® Sleep Technologies Announces Signing of Definitive Agreements for $30 Million of Convertible Notes
Financing will support Company's pending business combination and fund strategic growth initiatives SAN FRANCISCO, Aug. 27, 2022 /PRNewswire/ -- ProSomnus Sleep Technologies ("ProSomnus"), the leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the execution of definitive agreements with institutional investors led by funds affiliated with or managed by Cohanzick Management, LLC and...
Ascentage Pharma Announces 2022 Interim Results
SUZHOU, China and ROCKVILLE, Md. , Aug. 27, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its 2022 interim results. During the reporting period, Ascentage Pharma remained steadfastly committed to its strategy of global innovation...
Ocumension Releases its 2022 Interim Report with its core product Youshiying® being approved for marketing, continuously accelerating product commercialization
BEIJING, Aug. 26, 2022 /PRNewswire/ -- On August 26, 2022 (Beijing time), Ocumension Therapeutics (1477.HK) released its 2022 interim report. The Company's overall performance remained remarkable despite the fact that the pandemic caused considerable trouble in commercializing its ophthalmic products in the first half of the year. The Company achieved revenue of...
Waterdrop Releases User Family Insurance Report
BEIJING, Aug. 26, 2022 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, recently released the User Family Security Report. According to the survey of the users of Waterdrop Insurance Marketplace, the report shows that users' insurance purchase behaviors are highly associated...
Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases
GAITHERSBURG, Md. and SUZHOU, China, Aug. 26, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the advancement of its GalAhead™ RNAi delivery platform for developing novel therapeutic products focused on complement-related diseases. Among four product candidates developed with GalAhead™, STP144G, which targets Complement...
First approval of Cadonilimab (PD-1/CTLA-4 bispecific) published in Drugs, a peer-reviewed medical journal
HONG KONG, Aug. 26, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company committed to the research, development, manufacturing and commercialization of either first-in-class or best-in-class therapies, announced a review article featuring on Cadonilimab, a first-in-class PD-1/CTLA-4 bi-specific antibody developed by the company, was published in Drugs, a peer-reviewed medical...
Kira Pharmaceuticals to Present New Preclinical Data on Lead Asset KP104 at the 2022 European Meeting on Complement in Human Disease Conference
Oral presentation characterizes promising PK/PD properties of KP104 in relevant animal models and supports its further development as a potent bifunctional complement inhibitor suitable for both intravenous and subcutaneous administration Poster presentations demonstrate synergistic effects of selectively inhibiting both the alternative and terminal pathways to treat complement-driven diseases, including data from a...
VISTA Eye Specialists joins Qualitas Health Family to further strengthen Qualitas’ healthcare foothold in Asia Pacific
PETALING JAYA, Malaysia, Aug. 26, 2022 /PRNewswire/ -- VISTA Eye Specialists (VISTA) officially joins the Qualitas Health integrated network of clinics in Asia in a collaboration borne out of the attraction towards values that they share - to provide the Malaysians with access to quality healthcare services, technology, and a superior service experience - plus a passion to become...
Everest Medicines Announces the Departure of CEO, Kerry Blanchard
SHANGHAI, Aug. 26, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, today announced that Dr. Kerry Blanchard has resigned as Chief Executive Officer and as a member of the Board of Directors, effective immediately. He will remain...
